The 56 references in paper S. Avdeev N., С. Авдеев Н. (2015) “Обострения хронической обструктивной болезни легких: выбор антибактериальной терапии // Exacerbation of chronic obstructive pulmonary disease: a choice of antibacterial treatment” / spz:neicon:pulmonology:y:2014:i:6:p:65-72

1
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med.2010; 363: 1128–1138.
(check this in PDF content)
2
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2014. www.goldcopd.org
(check this in PDF content)
3
Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med.2006; 5: 343–349.
(check this in PDF content)
4
O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax. 2006; 61: 354–361. Группы терапии Плацебо АMK 1,0 0,8 0,6 0,4 0,2 0,0 0 100 200 300 400 Дни после начала исследования Интервал, свободный от обострений 233 дня 160 дней p = 0,015 Рис. 3. Период до следующего обострения при терапии обострений ХОБЛ с использованием АМК и плацебо Fig. 3. Time to the first exacerbation in patients treated with amoxicilline / clavulanate or placebo for COPD exacerbation
(check this in PDF content)
5
Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852.
(check this in PDF content)
6
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 1998; 151: 1418–1422.
(check this in PDF content)
7
Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121: 1449–1455.
(check this in PDF content)
8
Celli B.R., Barnes P.J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J.2007; 29: 1224–1238.
(check this in PDF content)
9
Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.JAMA.1995; 274: 1852–1857.
(check this in PDF content)
10
Connors A.F. Jr, Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.
(check this in PDF content)
11
Wouters E.F. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.
(check this in PDF content)
12
Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J. 2005; 26: 234–241.
(check this in PDF content)
13
Kong G.K., Belman M.J., Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest. 1997; 111: 89–94.
(check this in PDF content)
14
Han M.K., Agusti A., Calverley P.M. et al. COPD phenotypes: The future of COPD.Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
(check this in PDF content)
15
Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.
(check this in PDF content)
16
Aaron S.D., Donaldson G.C., Whitmore G.A. et al. Time course and pattern of COPD exacerbation onset. Thorax. 2012; 67: 238–243.
(check this in PDF content)
17
Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
(check this in PDF content)
18
Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD. 2006; 3: 109–115.
(check this in PDF content)
19
Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998; 113: 1542–1548.
(check this in PDF content)
20
Hirschmann J.V. Do bacteria cause exacerbations of COPD? Chest. 2000; 118: 193–203.
(check this in PDF content)
21
Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.1987; 106: 196–204.
(check this in PDF content)
22
Roede B.M., Bresser P., El Moussaoui R. et al. Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study.Clin. Microbiol. Infect. 2007; 13: 284–290.
(check this in PDF content)
23
Celli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper.Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
24
Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease.Respir. Med.1998; 92: 664–667.
(check this in PDF content)
25
Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Уральский медицинский журнал. 2008; 13: 19–24. / Avdeev S.N., Baymakanova G.E., Zubairova P.A. A role of C-reactive protein for diagnosis of bacterial infection and pneumonia in patients with exacerbation of chronic obstructive pulmonary disease. Ural'skiy meditsinskiy zhurnal. 2008; 13: 19–24 (in Russian).
(check this in PDF content)
26
Wilson R., Jones P., Schaberg T. et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax. 2006; 61: 337–342.
(check this in PDF content)
27
Woodhead M., Blasi F., Ewig S. et al. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections.Eur. Respir. J.2005; 26: 1138–1180.
(check this in PDF content)
28
Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. http://www.pulmonology.ru/publications/guide.php/ Federal guidelines on diagnosis and management of chronic obstructive pulmonary disease. Available at: http://www. pulmonology.ru/publications/guide.php(in Russian).
(check this in PDF content)
29
Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J.2007; 29: 1127–1137.
(check this in PDF content)
30
Anzueto A., Fisher C.L. Jr, Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72–86.
(check this in PDF content)
31
Amsden G.W., Baird I.M., Simon S., Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest. 2003; 123: 772–777.
(check this in PDF content)
32
Andre-Alves M.R., Jardim J.R., Silva R.F. et al. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J. Bras. Pneumol.2007; 33: 43–50.
(check this in PDF content)
33
Rubin B.K. Immunomodulatory properties of macrolides: overview and historical perspective.Am. J. Med. 2004; 117 (9A): 2S–4S.
(check this in PDF content)
34
EUCAST Expert rules in antimicrobial susceptibility testing, version 1, April 2008.http:// www.EUCAST.org
(check this in PDF content)
35
Яковлев С.В. Цефиксим – новый препарат в арсенале антибиотиков для лечения обострений ХОБЛ. Русский медицинский журнал. 2011; 8: 494–497. / Yakovlev S.V. Cefixime as a new antibiotic for therapy of COPD exacerbation. Russkiy meditsinskiy zhurnal.2011; 8: 494–497 (in Russian).
(check this in PDF content)
36
Козлов Р.С., Сивая О.В., Кречикова О.И. и др. Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС).Клиническая микробиология и антимикробная химиотерапия.2010; 12 (4): 329–341. / Kozlov R.S., Sivaya O.V., Krechikova O.I. et al. Streptococcus pneumonia antibiotic resistance trend in Russia, 1999–2009 (Results of multicenter prospective study PeGAS). Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2010; 12 (4): 329–341 (in Russian).
(check this in PDF content)
37
Cazzola M., Vinsiguerra A., Beghi G. et al. Comparative evaluation of the clinical and microbiological efficacy of coamoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J. Chemother.1995; 7 (5): 432–441.
(check this in PDF content)
38
Lorenz J., Steinfeld P., Drath L. et al. Efficacy and tolerability of 5- vs 10-day cefixime therapy in acute exacerbations of chronic bronchitis.Clin. Drug Investig. 1998; 15: 13–20.
(check this in PDF content)
39
O'Donnell D.E., Hernandez P., Kaplan A. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J.2008; 15 (Suppl. A): 1A–8A.
(check this in PDF content)
40
O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691–716.
(check this in PDF content)
41
Blasi F., Tarsia P., Aliberti S. et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Therap.2006; 19: 11–19.
(check this in PDF content)
42
Lode H., Eller J., Linnhoff A., Ioanas M. The Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval.Eur. Respir. J.2004; 24: 947–953.
(check this in PDF content)
43
Sethi S., Fogarty C., Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis.Respir. Med.2004; 98: 697–707.
(check this in PDF content)
44
Wilson R., Allegra L., Huchon G. et al. MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004; 125: 953–964.
(check this in PDF content)
45
Geddes A.M., Klugman K.P., Rolinson G.N. Introduction: historical perspective and development of amoxicillin / clavulanate.Int. J. Antimicrob. Agents.2007; Suppl. 2: S109–S112.
(check this in PDF content)
46
McIvor R.A. Antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Can. Fam. Physician. 2009; 55: 15–16, 19–21.
(check this in PDF content)
47
Сидоренко С.В., Козлов С.Н. Группа пенициллинов. В кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н., ред. Практическое руководство по антиинфекционной химиотерапии. М.: Боргес; 2002. 47–55. / Sidorenko S.V., Kozlov S.N. Penicillines. In: Strachunskiy L.S., Belousov Yu.B., Kozlov S.N., eds. Practical handbook on antimicrobial chemotherapy. Moscow, Borges; 2002. 47–55 (in Russian).
(check this in PDF content)
48
Beghi G., Berni F., Carratu L. et al. Efficacy and tolerability of azithromycin versus amoxicillin clavulanic acid in acute purulent exacerbation of chronic bronchitis. J. Chemother. 1995; 7: 146–152.
(check this in PDF content)
49
Canut A., MartIn-Herrero J.E., Labora A., Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model.J. Antimicrob. Chemother. 2007; 60: 605–612.
(check this in PDF content)
50
Wilson R., Anzueto A., Miravitlles M. et al. Moxifloxacin vs amoxicillin / clavulanic acid in outpatient AECOPD: MAESTRAL results.Eur. Respir. J.2012; 40: 17–27.
(check this in PDF content)
51
Llor C., Moragas A., Hernández S. et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2012; 186: 716–723.
(check this in PDF content)
52
Puhan M.A., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res.2007; 8: 30.
(check this in PDF content)
53
Cortvriendt W.R., Verschoor J.S., Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung. 1987; 37: 977–979.
(check this in PDF content)
54
Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator film-coated tablet.Int. J. Clin. Pharmacol. Ther.2001; 39: 75–82.
(check this in PDF content)
55
Карпов О.И. Флемоклав Солютаб – новая лекарственная форма амоксициллина / клавуланата в лечении синусита. Клиническая фармакология и терапия. 2006; 15 (4): 1–4. / Karpov O.I. Flemoclav Solutab as a novel drug formulation of amoxicilline / clavulanate for therapy of sinusitis. Klinicheskaya farmakologiya i terapiya. 2006; 15 (4): 1–4 (in Russian).
(check this in PDF content)
56
Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: Открытое проспективное рандомизированное исследование. Пульмонология. 2008; 2:
(check this in PDF content)